Explore the words cloud of the McHAP project. It provides you a very rough idea of what is the project "McHAP" about.
The following table provides information about the project.
SZKOLA GLOWNA GOSPODARSTWA WIEJSKIEGO
|Coordinator Country||Poland [PL]|
|Total cost||1˙413˙750 €|
|EC max contribution||1˙413˙750 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||SZKOLA GLOWNA GOSPODARSTWA WIEJSKIEGO||PL (WARSZAWA)||coordinator||1˙413˙750.00|
The proposed project seeks to open a new research front within the field of drug delivery to the solid tumours. Unsatisfactory response of tumours to chemotherapy is mainly related to impaired diffusion of the anticancer drug because of decreased drug uptake due to poor vasculature. Moreover, the drug is not able to penetrate the most hypoxic sites. Cells from these ‘untreated’ sites are responsible for relapse and metastasis. However, these avascular regions attract macrophages that migrate even to areas far away from blood vessels. Therefore, they might constitute a unique delivery system of drug containing particles to these parts of the tumour mass. A promising example of such particles that could be used are ferritins, whose caged architecture allows for efficient drug encapsulation and whose uptake from macrophage cells has been well demonstrated. My recent ground breaking finding was that macrophages are also able to specifically and actively transfer these taken up ferritins (loaded with the compound of choice) to cancer cells. Thus, these preliminary results indicate the possibility to use macrophages to deliver ferritin encapsulated compounds directly to the tumour cells even in its hypoxic areas. Then, the use of hypoxia-activated prodrugs (HAP) which are selectively activated only in hypoxic regions will be exploited in order to make cancer therapy safer. However, the molecular mechanism of ferritin uptake by macrophages, their storage, and transport to the cancer cells represent key issues to be investigated and pave the way to the experimental design of the present project. In the present project, we will develop and characterize a completely new and modern approach to anticancer therapy and drug delivery. As such we expect to be able to precisely administer drugs to the tumour site (even to the hypoxic regions) where it is activated by tumour-specific conditions, avoiding side effects of anticancer therapy.
|year||authors and title||journal||last update|
M. Bialasek, M. Kubiak, M. Gorczak, A. Braniewska, P. Kucharzewska-Siembieda, M. Krol, B. Taciak
Exploiting iron-binding proteins for drug delivery
published pages: 675-685, ISSN: 0867-5910, DOI: 10.26402/jpp.2019.5.03
|Journal of Physiology and Pharmacology 2019, 70, 5||2020-03-20|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MCHAP" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MCHAP" are provided by the European Opendata Portal: CORDIS opendata.